
price close busi august
biomed devic servic
best show execut come ahead
product cycl buy pt
bottom line quarter came bullish expect upsid
street estim vs consensu far exceed expect
blow-out revenu came cg/street estim
quarter support broad ww strength includ robust sensor volum
ou sale us new patient add compani continu benefit surg
cgm awar view technolog superior product look
forward still earli stage roll us
contribut continu drive patient awar dtc invest
expect support robust new patient addit year-end lastli
impress execut ou remain earli day strong pipelin
underpin believ durabl outlook top-lin growth
beyond sum come confid abil deliv
upsid current estimates/guid especi heel new product launch
buy
result post revenu y/i top-lin strength
support broad strength across segment includ ou growth xfx
us growth y/i specif us sale benefit increas market
awar accept cgm led acceler medicar
commerci channel manag highlight dtc advertis
includ libr help drive broader patient awar cgm someth
expect continu impact
transient expens relat open new az manufactur facil
well faster anticip ramp manufactur capac meet robust
demand result manag lower gm expect
adjust ep came cg/street estim
drove beat look growth manag highlight robust
demand recent launch remind investor beat driven
primarili adopt support stronger ever market awar
accept cgm point biggest constraint
manufactur inventori level given unpreced demand new
exist patient manag note hope manufactur overhang
allevi exit look forward manag reiter expect
meaning product cycl given increas market awar meaning
use extend sensor wear time day addit detail survey
note
ou growth xfx ou impress reimburs tailwind
strength key direct sale market manag highlight signific ou
busi make total revenu reiter plan continu
invest ou commerci infrastructur
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
guidanc chang estim
given strong increas revenu guidanc
rang y/i previous manag expect
growth support sensor volum ou expans ww instal base
gross margin guidanc lower rang given
on-going margin pressur associ faster expect ramp
product subsequ opex expect increas y/i
y/i previous made follow chang estim
buy unchang target price august
biomed devic servic
resultsactualcg estbeat/miss beat/miss consensusbeat/miss total revenu total gross oper result categoryactualcg estbeat/missbeat/miss prior yeary/i growthnet sale
figur summari estim revis
high-growth med-tech comp group current trade mean ev/sal multipl
estim revenu sum increas price target
base valuat ev/sal multipl appli
revenu estim price target assum cash
debt share outstand
figur matrix discount rate impli share price target
buy unchang target price august
biomed devic servic
except ep newold newold newold product comp ev/sal multipl price metric use ev/sal valuat growth medic devic ev/sal multipl sale share outstand figur dexcom incom statement
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price august
biomed devic servic
canaccord genuiti estim compani report compani report
buy unchang target price august
biomed devic servic
